Jpmorgan Chase & CO Renovo Rx, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 36 shares of RNXT stock, worth $46. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36
Previous 40
10.0%
Holding current value
$46
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RNXT
# of Institutions
29Shares Held
11MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD3.47MShares$4.51 Million1.85% of portfolio
-
Awm Investment Company, Inc. New York, NY2.29MShares$2.97 Million0.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.35MShares$1.75 Million0.0% of portfolio
-
Bank Of The West975KShares$1.27 Million0.27% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL689KShares$895,1500.0% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $11.8M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...